Sensus Healthcare Inc
sensushealthcare.comSensus Healthcare (NASDAQ: SRTS) is a medical device company that develops and sells superficial radiation therapy systems for non-melanoma skin cancer treatment and post-surgical keloid scar prevention. Revenue comes from device sales of its SRT-100, SRT-100+, and SRT-100 Vision product line, supplemented by a recurring Sentinel service program covering parts, labor, and preventive maintenance under contract. The company also generates revenue through Sensus Healthcare Services, LLC, a wholly owned subsidiary formed in February 2024 that provides operational healthcare services to dermatology clinics, including equipment, radiation oncology and physicist oversight, and on-site radiotherapy technologist staffing. Incorporated in Delaware and headquartered in Boca Raton, Florida, Sensus was organized in 2010 and completed its IPO in 2016. Total revenues were $27.5 million in FY2025 and $41.8 million in FY2024, with the company reporting a net loss of $7.7 million in FY2025 versus net income of $6.6 million in FY2024. The company has never declared a dividend and operates as a single segment.
Products & Services
SRT-100: base superficial radiation therapy device. SRT-100+: adds Sentinel service program eligibility and additional features. SRT-100 Vision: adds high-frequency ultrasound imaging, volumetric tumor analysis, beam margins planning, dosimetry parameters, and full treatment documentation. Sentinel service program: parts, labor, and annual preventive maintenance contract. Sensus Healthcare Services, LLC: operational healthcare services to dermatology clinics including device access, radiation oncology and physicist oversight, and on-site radiotherapy technologist staffing.
Revenue Model
Transactional device sales (SRT-100, SRT-100+, SRT-100 Vision), recurring service contracts (Sentinel program covering parts, labor, and annual preventive maintenance), and fee-based healthcare services through Sensus Healthcare Services, LLC (equipment, radiation oncology oversight, physicist oversight, and on-site technologist staffing to dermatology clinics).
Customers & Markets
Dermatology clinics and dermatologists treating non-melanoma skin cancer and post-surgical keloid scars. Reimbursement is covered by Medicare Part B and a number of private insurers in the U.S. for both non-melanoma skin cancer and keloid treatments using the SRT-100. International markets are also served, with reimbursement approval required on a country-by-country basis.
Geographic Exposure
Primary market is the United States, with Medicare and private insurer reimbursement coverage. International operations exist with country-by-country reimbursement approval required, though no specific international revenue breakdown is provided in the filing excerpts.
Financial Snapshot
Loading...
